The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment
of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown …

Simple Summary Immune checkpoint inhibitors (ICIs) are now a cornerstone of systemic
treatment for hepatocellular carcinoma (HCC). However, their efficacy is blunted by …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths in the
world, and for patients with advanced disease there are few therapeutic options available …

Immune-modulatory therapy, especially with immune-checkpoint inhibitors (ICIs), has
reshaped cancer therapeutics. Immunotherapy is relatively a novel approach that can …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since
most patients are diagnosed at advanced stage and the current systemic treatment options …

The position of immunotherapy as a pillar of systemic cancer treatment has been firmly
established over the past decade. Immune checkpoint inhibitors are a welcome option for …

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for
various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical …

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer
worldwide, and the overall survival of patients with unresectable disease is poor. In the last …